Online inquiry

IVTScrip™ mRNA-Anti-tcdA, CDA 1(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5455MR)

This product GTTS-WQ5455MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets tcdA gene. The antibody can be applied in Clostridium difficile infectious diarrhea research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq WP_009902072.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 57299391
UniProt ID P16154
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-tcdA, CDA 1(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ5455MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2453MR IVTScrip™ mRNA-Anti-TSLP, AMG 157(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA AMG 157
GTTS-WQ10674MR IVTScrip™ mRNA-Anti-TNFSF13B, LymphoStat-B(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA LymphoStat-B
GTTS-WQ7717MR IVTScrip™ mRNA-Anti-GLP1R, GLP-1Fc(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA GLP-1Fc
GTTS-WQ14404MR IVTScrip™ mRNA-Anti-IFNA1, RhuMAB IFNalpha(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA RhuMAB IFNalpha
GTTS-WQ3870MR IVTScrip™ mRNA-Anti-IL6R, BCD-089(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA BCD-089
GTTS-WQ131MR IVTScrip™ mRNA-Anti-CA9, 124I_WX-G250(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA 124I_WX-G250
GTTS-WQ14118MR IVTScrip™ mRNA-Anti-NGF, aNGF75(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA aNGF75
GTTS-WQ12386MR IVTScrip™ mRNA-Anti-SAA1, NEOD-001(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA NEOD-001
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW